Business Wire

CA-ULTRAVIOLET-DEVICES

Share
UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet (3.65 Meters) Distance in 5 Minutes

UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10 , inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters). Testing on the coronavirus strain that causes the COVID-19 disease was conducted by Innovative Bioanalysis, a CAP, CLIA, and BEI-recognized BSL-3 certified laboratory (CA, USA). The Centers for Disease Control and Prevention (CDC) has indicated that the COVID-19 disease can be spread by both surface and airborne transmission of SARS-CoV-2.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005585/en/

The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals. The UVDI-360 Room Sanitizer has previously been proven to help prevent Healthcare-Associated Infections and to inactivate over 35 pathogens, including human coronavirus (229E), in over 10 peer-reviewed published clinical studies and independent laboratory testing.

“We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.” stated Peter Veloz, Chief Executive Officer, UVDI. “Specific to use in hospitals for whole room disinfection, we believe that proving rapid inactivation of pathogens at distances of 8 feet (2.44 meters) and 12 feet (3.65 meters) is the best marker for in-facility performance. Independent confirmation of effectiveness against high-risk pathogens is a common sense, yet critical step to verify disinfecting claims for UV devices.”

“Building on our deep science-based evidence demonstrating the UVDI-360’s effectiveness against high-risk pathogens, including coronaviruses, we feel the healthcare professionals we serve globally deserve proof against the specific SARS-CoV-2 viral strain causing COVID-19,” added Dr. Ashish Mathur, Vice President of Innovation and Technology, UVDI.

About UltraViolet Devices, Inc.

UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California, applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate high-risk pathogens. UVDI’s proven Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).

1 https://www.cdc.gov/coronavirus

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye